Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Eli Lilly cuts the price of insulin, capping drug at $35 per month out-of-pocket

The moves announced Wednesday promise critical relief to some people with diabetes who can face annual costs of more than $1,000 for insulin they need in order to live.

WEKU

Diabetes Giant Eli Lilly Slashes Insulin Prices 70% In A Move Its CEO Calls 'Aggressive'

Eli Lilly announced a 70% price cut for most of its insulins Wednesday in a move its CEO described as "aggressive." Eli Lilly stock jumped.

Investors Business Daily

Under pressure, Eli Lilly cuts insulin prices 70%

Drugmaker Eli Lilly says it's cutting the price of one insulin to below 1990s levels.

Axios

From analysis to the latest developments in health,
read the most diverse news in one place.

Lilly plans to slash some insulin prices, expand cost cap

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay when they fill prescriptions

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily…

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The 5 Safest Stocks You Can Buy in 2023

The stock market might remain volatile in the near term amid the still-alarmingly high inflation and the anticipated continuation of rate hikes. Therefore, fundamentally strong Eli Lilly (LLY), Novartis (NVS), Comcast (CMCSA), HCA Healthcare (HCA), and Myers Industries (MYE), which pay steady dividends, might be safe buys now. Read more.

StockNews.com

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

Eli Lilly Dives After A 'Bump In The Road' Shakes Its Newest Diabetes Drug

Eli Lilly experienced a "bump in the road" for its newest diabetes treatment, Mounjaro, an analyst said Thursday as LLY stock toppled.

Investors Business Daily

Eli Lilly Tops Q4 Earnings Forecast, Lifts 2023 Outlook, On Trulicity Strength

"Over the course of this critical year, we hope to launch as many as four new medicines for challenging diseases, while advancing our next generation of molecules currently in Phase 3." said CEO David Ricks.

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug

Eli Lilly stock dipped Friday after the FDA unexpectedly rejected its request for an accelerated approval of its Alzheimer's treatment.

The Independent UK

Lilly shares slip as FDA seeks more Alzheimer's drug data

Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment

Tribune News Service

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

Investors Business Daily

How Novo Nordisk Just Expanded Its Diabetes Lead Over Pfizer, Eli Lilly

The Food and Drug Administration expanded the label for Novo Nordisk's oral diabetes medicine, leading NVO stock to jump Friday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD Stock Of The Day: How These Issues In 2023 Could Spark, Or Slam, Eli Lilly Stock

Eli Lilly is the IBD Stock Of The Day as the company explores new methods of treating Alzheimer's and obesity, driving LLY stock near highs.

Tribune News Service

A TikTok trend sold out Ozempic, leaving people with diabetes dizzy, scared

For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn’t been able to get his diabetes medication.

Investors Business Daily

The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock

Investors are closely watching two Eli Lilly battles that will unfold in 2023 as LLY stock continues a fevered streak, tacking on new highs.

StockNews.com

3 Large-Cap Stocks to Add to Your Portfolio Now

The Fed’s aggressive stance on inflation has weighed heavily on the stock market this year. As large-cap stocks usually can weather challenging economic conditions, sound large-cap stocks Eli Lilly (LLY), Agilent Technologies (A), and Fortinet (FTNT) might be wise additions to your portfolio. Keep reading.

Investors Business Daily

The Bullish Call Eli Lilly Made For Its Next-Gen Obesity Drug, A Rival To Novo, Amgen

Eli Lilly said Tuesday it plans to advance its next-generation obesity treatment into final-phase testing, but LLY stock dipped on guidance.

Investors Business Daily

How An Eli Lilly Decision Could Light Up The Red-Hot Obesity Landscape — Again

A key decision from Eli Lilly could alight the obesity treatment landscape again, an analyst said Friday as LLY stock lingers near a record.

Investors Business Daily

Here's What We Know So Far About Amgen's Obesity Drug As It Trails Novo Nordisk, Eli Lilly

Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.